Edition:
United States

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

265.90CHF
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
CHF265.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
300,969
52-wk High
CHF270.80
52-wk Low
CHF144.69

Latest Key Developments (Source: Significant Developments)

Lonza ‍expands offerings for early phase biopharmaceutical drug development​
Thursday, 2 Nov 2017 10:48am EDT 

Nov 2 (Reuters) - Lonza Group Ag :Says ‍expands service offerings for early phase biopharmaceutical drug development​.  Full Article

Lonza says not planning to sell wood preservation business after fixes
Thursday, 26 Oct 2017 09:34am EDT 

Oct 26 (Reuters) - Lonza Group Ag :Says wood preservation business 'definitely not under a question mark at this time,' when asked if company would consider selling ‍​.Says wood preservation business performance 'dramatically' better than 3-4 years ago when company considered selling it‍​.  Full Article

Lonza raises guidance for core EBIT growth in 2016
Wednesday, 20 Jul 2016 01:04am EDT 

Lonza Group AG : Raising its guidance for core ebit growth and now expects a double-digit improvement in core ebit for full year of 2016 .Strong cash flow generation is expected to further reduce net debt significantly by end of fiscal year 2016.  Full Article

Lonza Group: Rodolfo Savitzky to succeed Toralf Haag as CFO
Tuesday, 10 May 2016 01:15am EDT 

Lonza Group AG : Rodolfo Savitzky to succeed Toralf Haag as Lonza Group CFO .Change will be effective as of October 1, 2016, when Rodolfo Savitzky will also succeed Toralf Haag as a member of Lonza Executive Committee.  Full Article

Lonza Group comments on first half of FY 2016 earnings outlook
Tuesday, 26 Apr 2016 01:00am EDT 

Lonza Group AG:Double-Digit core EBIT growth expected for first half of FY 2016.  Full Article

Lonza Group gives FY 2016 guidance and comments on mid-term FY 2018 outlook, proposes dividend
Wednesday, 27 Jan 2016 01:00am EST 

Lonza Group AG:‍In 2016 Lonza is expected to grow sales in line with 2018 guidance and targets a core EBIT growth of above 5 pct​.Sees ‍core EBITDA approaching 1 billion Swiss francs in 2018​ ‍.Sees ‍sales growth of low to mid-single digits on average per year until 2018​​.Proposing a stable dividend of 2.50 Swiss francs per share for FY 2015.  Full Article

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)